SCHEMBL942386

SCHEMBL942386

CC(C=Cc1ccccc1)=NNC(N)=S

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 1.00
ALDH1A1 P00352 2/20 1.00
MAPT P10636 2/20 1.00
NPSR1 Q6W5P4 1/20 1.00
EGFR P00533 12/20 0.66
SMN1; SMN2 Q16637 2/20 0.65
RAB9A P51151 1/20 0.56
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
ALOX15 P16050 1/20 0.54
ATM Q13315 1/20 0.54
METTL3 Q86U44 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27614771 0.83 NPSR1 (0.71) GAAALDH1A1MAPTNPSR1EGFR
SCHEMBL28256362 0.82 ALDH1A1 (0.69) GAAALDH1A1MAPTNPSR1EGFR
SCHEMBL9369768 0.80 MAPT (0.67) GAAALDH1A1MAPTNPSR1SMN1; SMN2
SCHEMBL28198725 0.79 EGFR (1.00) EGFR
SCHEMBL27893763 0.79 EGFR (1.00) EGFR
SCHEMBL10403455 0.75 MAPT (0.61) GAAALDH1A1MAPTNPSR1EGFR
SCHEMBL10016574 0.73 SMN1; SMN2 (0.59) GAAALDH1A1MAPTNPSR1SMN1; SMN2
SCHEMBL14950318 0.73 RAB9A (0.69) GAAALDH1A1MAPTNPSR1SMN1; SMN2
SCHEMBL14667486 0.71 ALOX15 (1.00) GAAALDH1A1MAPTNPSR1SMN1; SMN2
SCHEMBL5799187 0.71 ALOX15 (1.00) GAAALDH1A1MAPTNPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318782-B2 Mitotic kinesin inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-11-27 US disclosed
US-20110275827-A1 Mitotic Kinesin Inhibitor FUJIFILM CORPORATION (JP) 2011-11-10 US disclosed
EP-1454903-B9 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2011-10-05 EP disclosed
CN-101787000-B M-stage kinesin inhibitor KYOWA HAKKO KOGYO KK 2011-08-03 CN disclosed
EP-2327702-A1 Mitotic kinesin inhibitor Kyowa Hakko Kirin Co., Ltd. (JP) 2011-06-01 EP disclosed
US-7902234-B2 Thiadiazoline derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-03-08 US disclosed
US-20110004000-A1 Mitotic Kinesin Inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-01-06 US disclosed
US-7851635-B2 Mitotic kinesin inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-12-14 US disclosed
US-20100240716-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-09-23 US disclosed
EP-1454903-B1 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2010-09-08 EP disclosed
US-7425636-B2 Thiadiazoline derivative KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-09-16 US disclosed
US-20080207706-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD (JP) 2008-08-28 US disclosed
EP-1847534-A2 Thiadiazoline derivative Kyowa Hakko Kogyo Co., Ltd (JP) 2007-10-24 EP disclosed
US-20070213380-A1 Thiadiazoline derivative KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-09-13 US disclosed
US-20070155804-A1 Mitotic kinesin inhibitor KYOWA HAKKO KOGYO CO., LTD. OF TOKYO, JAPAN FUJI PHOTO FILM CO., LTD. KANAGAWA, JAPAN 2007-07-05 US disclosed
CN-1774428-A M-phase kinesin inhibitors KYOWA HAKKO KOGYO KK (JP) 2006-05-17 CN disclosed
US-20060074113-A1 Thiadiazoline derivative KYOWA KIRIN CO., LTD. (JP) 2006-04-06 US disclosed
EP-1616866-A1 M-STAGE KINESIN INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-01-18 EP disclosed
CN-1617864-A thiadiazoline derivatives KYOWA HAKKO KOGYO KK (JP) 2005-05-18 CN disclosed
EP-1454903-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074113-A1 Thiadiazoline derivative BRWD1, RB1, ARG2 GAA 4130/4885ALDH1A1 343/4885MAPT 4584/4885
US-20070155804-A1 Mitotic kinesin inhibitor KIF15, KIF5A, KIF5B GAA 1882/4885ALDH1A1 2889/4885MAPT 254/4885
US-20070213380-A1 Thiadiazoline derivative BRWD1, RB1, ARG2 GAA 4130/4885ALDH1A1 343/4885MAPT 4584/4885
US-20110004000-A1 Mitotic Kinesin Inhibitor KIF15, KIF5A, KIF5B GAA 1882/4885ALDH1A1 2889/4885MAPT 254/4885
US-20100240716-A1 THIADIAZOLINE DERIVATIVE BRWD1, WDR82, RB1 GAA 3801/4885ALDH1A1 459/4885MAPT 4615/4885
US-20080207706-A1 THIADIAZOLINE DERIVATIVE BRWD1, RB1, ARG2 GAA 4130/4885ALDH1A1 343/4885MAPT 4584/4885
US-20110275827-A1 Mitotic Kinesin Inhibitor KIF15, KIF5A, KIF5B GAA 1882/4885ALDH1A1 2889/4885MAPT 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.